Knockdown of chemokine receptor CXCR4 gene by RNA interference: Effects on the B16-F10 melanoma growth

André,Nayara  Delgado; Silva,Viviane  Aline Oliveira; Watanabe,Maria  Angelica Ehara; De Lucca,Fernando   Luiz

doi:10.3892/or.2016.4620

Knockdown of chemokine receptor CXCR4 gene by RNA interference: Effects on the B16-F10 melanoma growth

Authors:
- Nayara Delgado André
- Viviane Aline Oliveira Silva
- Maria Angelica Ehara Watanabe
- Fernando Luiz De Lucca
View Affiliations

Affiliations: Federal University of Sao Joao del‑Rei, 35501296 Divinópolis, MG, Brazil, Molecular Oncology Research Center, Barretos Cancer Hospital, 14784-400 Barretos, SP, Brazil, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, 86057‑970 Londrina, PR, Brazil, Department of Biochemistry and Immunology, Ribeirao Preto Medical School, University of São Paulo, 14049‑900 Ribeirao Preto, SP, Brazil
Published online on: February 12, 2016 https://doi.org/10.3892/or.2016.4620
Pages: 2419-2424

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of malignant melanoma has increased greatly in recent decades presenting a high mortality rate despite intensive efforts in this area of research. Recent studies indicate that the chemokine receptor 4 (CXCR4) plays a critical role in cancer. Thus, it has been reported that CXCL12 binding to CXCR4 initiates various downstream signaling pathways that result in a plethora of responses involved in cell proliferation and metastasis. Recently, we demonstrated that CXCR4 silencing by RNA interference (RNAi) significantly reduced the number of pulmonary metastatic nodules. In the present study, we examined the effect of the intratumoral injection of CXCR4 short hairpin (shRNA) expressing plasmids on the growth of B16‑F10 melanoma in mice. In vitro transfection of these tumor cells with CXCR4 shRNA expressing plasmid (CXCR4 shRNA) significantly reduced the levels of CXCR4 mRNA (85%) and CXCR4 protein (70%) compared with the control. We showed that the tumor growth was significantly reduced (66%) in mice inoculated with transfected B16‑F10 melanoma cells when compared with the control group. We also found that the intratumoral injection of CXCR4 shRNA expressing plasmids results in a significant inhibition (70%) of B16‑F10 melanoma growth. This finding supports the hypothesis that a direct administration of RNAi‑based therapeutics into the target tumor is a promising approach for overcoming the hurdles of systemic delivery. The present study is the first demonstration that CXCR4 plays a critical role in B16-F10 melanoma growth. Currently there is great interest in the development of antagonists for therapeutic targeting CXCR4 expression. Considering our results and the fact that CXCR4 is highly conserved between human and mouse, this experimental model of cancer may be useful for the discovery of new CXCR4 antagonists with clinical implications.

View Figures

View References

1	Murdoch C: CXCR4: Chemokine receptor extraordinaire. Immunol Rev. 177:175–184. 2000. View Article : Google Scholar
2	Zlotnik A: Chemokines in neoplastic progression. Semin Cancer Biol. 14:181–185. 2004. View Article : Google Scholar : PubMed/NCBI
3	Toyozawa S, Kaminaka C, Furukawa F, Nakamura Y, Matsunaka H and Yamamoto Y: Chemokine receptor CXCR4 is a novel marker for the progression of cutaneous malignant melanomas. Acta Histochem Cytochem. 45:293–299. 2012. View Article : Google Scholar : PubMed/NCBI
4	Mitchell B, Leone D, Feller JK, Bondzie P, Yang S, Park HY and Mahalingam M: Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status. Melanoma Res. 24:621–625. 2014. View Article : Google Scholar : PubMed/NCBI
5	Payne AS and Cornelius LA: The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 118:915–922. 2002. View Article : Google Scholar : PubMed/NCBI
6	Longo-Imedio MI, Longo N, Treviño I, Lázaro P and Sánchez-Mateos P: Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer. 117:861–865. 2005. View Article : Google Scholar : PubMed/NCBI
7	Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G and Castello G: Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 11:1835–1841. 2005. View Article : Google Scholar : PubMed/NCBI
8	Scala S, Giuliano P, Ascierto PA, Ieranò C, Franco R, Napolitano M, Ottaiano A, Lombardi ML, Luongo M, Simeone E, et al: Human melanoma metastases express functional CXCR4. Clin Cancer Res. 12:2427–2433. 2006. View Article : Google Scholar : PubMed/NCBI
9	Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D and Jain RK: CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies? Clin Cancer Res. 17:2074–2080. 2011. View Article : Google Scholar : PubMed/NCBI
10	Fidler IJ: Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35:218–224. 1975.PubMed/NCBI
11	André ND, Silva VAO, Ariza CB, Watanabe MAE and De Lucca FL: In vivo silencing of CXCR4 with jetPEI/CXCR4 shRNA nanoparticles inhibits pulmonary metastasis of B16-F10 melanoma cells. Mol Med Rep. 12:8320–8326. 2015.
12	Li Z, Li N, Wu M, Li X, Luo Z and Wang X: Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol Cell Biochem. 381:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
13	Díaz MR and Vivas-Mejia PE: Nanoparticles as drug delivery systems in cancer medicine: Emphasis on RNAi-containing nanoliposomes. Pharmaceuticals (Basel). 6:1361–1380. 2013. View Article : Google Scholar
14	Li CX, Parker A, Menocal E, Xiang S, Borodyansky L and Fruehauf JH: Delivery of RNA interference. Cell Cycle. 5:2103–2109. 2006. View Article : Google Scholar : PubMed/NCBI
15	Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H and Harashima H: Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol Ther. 21:1195–1203. 2013. View Article : Google Scholar : PubMed/NCBI
16	Deharvengt SJ, Gunn JR, Pickett SB and Korc M: Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth. Cancer Gene Ther. 17:325–333. 2010. View Article : Google Scholar :
17	André ND, Silva VAO, Watanabe MAE and De Lucca FL: Intratumoral injection of PKR shRNA expressing plasmid inhibits B16-F10 melanoma growth. Oncol Rep. 32:2267–2273. 2014.PubMed/NCBI
18	Kumar R, Yoneda J, Fidler IJ and Dong Z: GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J Leukoc Biol. 65:102–108. 1999.PubMed/NCBI
19	Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TK and Tang T: Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies. Gene. 538:217–227. 2014. View Article : Google Scholar : PubMed/NCBI
20	Li T, Wu M, Zhu YY, Chen J and Chen L: Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs. Nucleic Acid Ther. 24:302–312. 2014. View Article : Google Scholar : PubMed/NCBI
21	Chatterjee S, Behnam Azad B and Nimmagadda S: The intricate role of CXCR4 in cancer. Adv Cancer Res. 124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
22	Heesen M, Berman MA, Benson JD, Gerard C and Dorf ME: Cloning of the mouse fusin gene, homologue to a human HIV-1 co-factor. J Immunol. 157:5455–5460. 1996.PubMed/NCBI